ImmuCell Corporation — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. ImmuCell develops and sells animal-health products, primarily First Defense for preventing scours in calves, and is developing Re-Tain for subclinical mastitis in dairy cows. Financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Product sales | $3.53 million | $3.86 million | $6.98 million | $9.86 million |
| Gross margin | $1.04 million (30%) | $1.71 million (44%) | $1.34 million (19%) | $4.81 million (49%) |
| Net loss | $1.38 million | $0.68 million | $3.69 million | $0.17 million |
| Net loss per share | $0.18 | $0.09 | $0.48 | $0.02 |
- First-half operating cash flow was negative $3.44 million, versus positive $1.01 million in 2022; capital expenditures were $1.39 million. Cash declined to $1.45 million from $5.79 million at year-end 2022.
- At June 30, working capital was approximately $6.75 million. Inventory was $7.54 million, up from $6.04 million at year-end, and included a $305,334 write-off of scrapped inventory during the first half.
- Debt obligations were approximately $9.73 million, excluding the $1.00 million line-of-credit balance outstanding at quarter-end. The line of credit was repaid early in Q3. Total liabilities also include operating lease liabilities of $4.37 million.
- In Q3, the company closed a further $3 million debt facility: a $2 million loan at 7% and a $1 million loan at 8%, each with a seven-year amortization schedule and a balloon payment due in three years.
Material changes and drivers
- Sales fell 9% year over year in Q2 and 29% in the first half. Management attributed the decline primarily to reduced production and product availability, rather than lower demand.
- Gross margin contracted sharply as lower production reduced fixed-cost absorption; the company also recorded contamination-related inventory write-offs. Operating losses widened to $1.30 million in Q2 and $3.56 million for the first half.
- Two contamination events—in late 2022 and Q1 2023—prompted a production slowdown and remediation. Management said quality-control tests met specifications throughout the four months ended August 4, 2023 and that it was resuming full production.
- The order backlog was approximately $7.9 million at June 30 and $8.5 million at August 4. Management cautioned that it includes aged, duplicate or potentially cancellable orders and may not convert fully to sales.
Outlook, risks and unusual items
- Management’s production goal is at least $6 million of product per quarter once full production resumes, equivalent to about 80% of stated annual capacity of approximately $30 million. June and July 2023 output averaged approximately $1.8 million per month, versus $1.1 million per month in the first five months of the year.
- The company deferred approximately $1.69 million of Re-Tain facility spending and approximately $3.7 million of First Defense expansion spending, citing first-half gross-margin losses. It also reduced its 2023 routine and miscellaneous capital spending budget by 50% for the time being.
- Management expects cash, product-sale gross margin and the Q3 $3 million facility to fund planned operations and capital needs for at least 12 months from filing. It estimated 2023 debt principal repayments of $1.2 million and interest expense of $458,000, including the new facility.
- Re-Tain still requires FDA approval. Four of five principal technical sections were complete; the company expected to submit its third CMC section shortly after filing and anticipated an FDA response after the statutory six-month review. Management estimated U.S. commercial sales could begin about eight months after submission if the section is completed and other requirements are met; its controlled-launch estimate is about $1 million in first-year sales and twice that in year two. These are estimates, not guarantees.
- In July, the USDA temporarily prohibited First Defense distribution and sales pending resolution of two inspection observations. The agency verbally rescinded the stop-distribution order on August 1 and the hold-release on August 4, allowing normal shipping to resume the week of August 7.
- Key risks include further contamination or production interruption, customer losses while orders are backlogged, dependence on two large distributors (78% of first-half sales; 74% of receivables at June 30), inflation and supply constraints, Re-Tain regulatory and launch uncertainty, and debt-service covenant requirements. The 2023 covenant was waived; a 1.35 minimum debt-service coverage ratio applies to specified trailing periods in 2024.
- Management identified a material weakness in financial reporting controls: depreciation had not been properly capitalized into inventory. The potential $387,000 inventory understatement was detected and corrected before filing; management said it was implementing remediation. Disclosure controls were assessed as effective.
Investor verification points
- Track whether production and quality results sustain the claimed recovery, and whether backlog converts into shipped sales without further regulatory interruption.
- Confirm cash use, borrowing and debt-service capacity, including the effect of the higher-rate Q3 loans and the company’s ability to meet future coverage covenants.
- Monitor Re-Tain’s third CMC submission, FDA review and inspection status, contract-manufactured supply, and timing and cost of the in-house facility.
- Assess whether gross margins recover as volume improves, given contamination costs, variable biological yields, inflation and deferred capital projects.
- Follow remediation of the material weakness and consider continued reliance on a concentrated product line, customer base and distribution channel.